Thanks for posting this Brentie.

This kind of development is Mannkind's biggest threat. Fortunately Mannkind is quite a bit ahead in getting to market. Speeding Afrezza's adoption rate is going to be important and another reason that a partnership is so important.

That being said, I think that FIAsp is still injected subcutaneously, so I would expect it to be slower than Afrezza. How does that affect its duration? Any comments?